Collaborative and Other Relationships - Prelude (Details) - USD ($) $ / shares in Units, $ in Thousands |
1 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
Nov. 30, 2025 |
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| License agreements | ||||
| Research and development | $ 2,050,152 | $ 2,606,848 | $ 1,627,594 | |
| Long term equity investments | 47,991 | $ 18,814 | ||
| Investment in Prelude | ||||
| License agreements | ||||
| Payments to acquire equity securities | $ 25,000 | |||
| Investment owned (in shares) | 6,250,000 | |||
| Non-voting common stock (in dollars per share) | $ 4.00 | |||
| Long term equity investments | $ 7,900 | 18,100 | ||
| Unrealized gain on equity investments | $ 10,300 | |||
| Prelude | ||||
| License agreements | ||||
| Payment to acquire license agreement | 60,000 | |||
| Upfront payment under license agreement | 35,000 | |||
| Research and development | 17,100 | |||
| Milestone payment made under license agreement | 100,000 | |||
| Prelude | Clinical And Regulatory Milestones And Single Digit Royalties On Global Net Sales | Maximum | ||||
| License agreements | ||||
| Additional milestone payments under the license agreement | $ 775,000 | |||
| X | ||||||||||
- Definition Represents the additional milestone payments to be made under the license agreement. No definition available.
|
| X | ||||||||||
- Definition License Agreement, Consideration Transferrable For Purchase Option No definition available.
|
| X | ||||||||||
- Definition Represents the amount of the upfront payment made under the license agreement. No definition available.
|
| X | ||||||||||
- Definition Payments To Acquire License Agreement No definition available.
|
| X | ||||||||||
- Definition Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of shares of investment owned. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Price of a single share of a number of saleable stocks of a company. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|